Although there is significant evidence supporting the involvement of ET-1 in the pathophysiology of hypertension [13], clinical trials have not yet convincingly demonstrated the efficacy of ET receptor antagonists as a treatment for systemic or resistant hypertension. This evidence concerns the gene EDN1 and Hypertension.